Accrued Expenses

12 Months Ended

Dec. 31, 2019

8.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

	December 31,
	2019		2018
Accrued clinical operations and trials costs	$	14,242,669	$	4,914,881
Accrued product development costs		3,573,231		2,222,093
Accrued compensation		3,673,111		2,253,621
Accrued other		958,928		460,596
Total	$	22,447,939	$	9,851,191